Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
8.56M
-
Number of holders
-
113
-
Total 13F shares, excl. options
-
89.6M
-
Shares change
-
-12.7M
-
Total reported value, excl. options
-
$144M
-
Value change
-
-$26M
-
Put/Call ratio
-
0.01
-
Number of buys
-
57
-
Number of sells
-
-70
-
Price
-
$1.61
Significant Holders of Atara Biotherapeutics, Inc. - Common Stock (ATRA) as of Q2 2023
150 filings reported holding ATRA - Atara Biotherapeutics, Inc. - Common Stock as of Q2 2023.
Atara Biotherapeutics, Inc. - Common Stock (ATRA) has 113 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 89.6M shares
.
Largest 10 shareholders include BAUPOST GROUP LLC/MA (9.77M shares), WASATCH ADVISORS LP (8.28M shares), BlackRock Inc. (8.26M shares), JPMORGAN CHASE & CO (7.72M shares), VANGUARD GROUP INC (6.95M shares), MAVERICK CAPITAL LTD (6.29M shares), Redmile Group, LLC (6.05M shares), GOLDMAN SACHS GROUP INC (4.56M shares), D. E. Shaw & Co., Inc. (4.35M shares), and STATE STREET CORP (2.54M shares).
This table shows the top 113 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.